Blood Cultures Fail the Smallest Patients

Neonatal sepsis kills an estimated 345,000 newborns per year globally — approximately 15% of all neonatal deaths. The incidence in low- and middle-income countries is 49-170 per 1,000 live births, compared to 1-4 per 1,000 in high-income countries. Blood culture, the diagnostic gold standard, is functionally useless in most LMIC neonatal units: 68% of septic neonates have bacteremia below 10 CFU/mL, the tiny blood volumes obtainable from newborns yield false-negative rates up to 60%, and results take 24-36 hours — far too slow for a condition where hours determine survival. In a study across 61 hospitals in four African countries, 70% of neonates received antibiotics but only 6% had a blood culture submitted.

Without diagnostic confirmation, clinicians in LMICs treat empirically: broad-spectrum antibiotics for every febrile neonate. This drives antimicrobial resistance — the WHO explicitly frames this TPP as an AMR intervention. An estimated 84% of neonatal infection deaths could be prevented through early diagnosis and appropriate management. The WHO's 2025 TPP defines two priority use cases — primary health care (where most neonates first present) and hospital-level care — but no existing diagnostic meets the specifications for either.

C-reactive protein (CRP) is the most widely used biomarker but rises 6-12 hours after infection onset, missing early-onset sepsis when intervention is most critical. Procalcitonin (PCT) rises faster (2-4 hours) and has better sensitivity, but costs are prohibitive in resource-poor settings and diagnostic accuracy ranges widely (67-92%). Combined CRP + PCT panels improve sensitivity but neither achieves standalone diagnostic reliability. Molecular methods (PCR, next-generation sequencing) offer speed and sensitivity but require laboratory infrastructure, electricity, and trained operators unavailable in most LMIC primary care settings. The fundamental constraint is biological: neonatal sepsis presents with nonspecific signs, has low and variable bacterial loads in blood, and requires a test that works with <100 microliters of blood in settings with minimal infrastructure.

The WHO TPP specifies: turnaround time <30 minutes, sensitivity >=90%, blood volume <100 microliters, functional at both point-of-care and hospital levels. Meeting this requires either novel host-response biomarker panels that outperform CRP/PCT (likely multiplex combinations of cytokines, acute-phase proteins, and transcriptomic signatures) or microfluidic platforms that can detect pathogens directly from microliter blood volumes without culture. A student contribution could address the biomarker discovery side: systematically evaluating which combinations of commercially available biomarkers best discriminate bacterial sepsis from viral infection and non-infectious inflammation in neonates.

A team could design a multiplex lateral flow assay prototype targeting 3-5 host-response biomarkers (e.g., CRP + PCT + IL-6 + IP-10) optimized for neonatal blood volumes (<50 microliters from heel prick), benchmarking it against clinical sepsis diagnosis in a neonatal unit. The engineering challenge is maintaining quantitative accuracy across multiple analytes on a single low-cost strip. Alternatively, a team could develop a machine learning clinical decision support tool that combines available bedside signs with rapid CRP results to improve antibiotic stewardship in settings where advanced diagnostics are unavailable. Relevant disciplines: biomedical engineering, neonatology, immunology, data science.